Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

September 13th 6:00 – 8:30 p.m.

- Executive Session 6:00 - 6:30
- Introductions and Approval of DUR Board Minutes 6:30 - 6:35
  (Public Comment Prior to Board Action)
- DVHA Pharmacy Administration Updates 6:35 - 6:40
  Updates
- Medical Director Update 6:40 – 6:45
  - Clinical Programs Update
  - Prescriber Comments
- Follow-up Items from Previous Meetings 6:45 – 6:55
  Overuse of Butalbital Containing Drugs initiative
- RetroDUR/DUR 6:55 – 7:10
  - Data Presentation: Diabetes/HTN-Appropriate
    Use of Angiotensin Modulators
  - Introduce: Proposed RetroDUR Initiatives for 2017
- Clinical Update: Drug Reviews 7:10 – 7:45
  (Public comment prior to Board action)
  Abbreviated New Drug Reviews
  - None

Full New Drug Reviews
- Adzenys XR® ODT (Amphetamine Extended-release ODT) (included in the Stimulants Therapeutic Drug Class Review)
- Spritam® tablets (levetiracetam)
- Zepatier® tablets (elbasvir and grazoprevir)
- Dyanavel XR® suspension (amphetamine) (included in the Stimulants Therapeutic Drug Class Review)
- Quillichew ER® chewable tablets (methylphenidate hydrochloride) (included in the Stimulants Therapeutic Drug Class Review)
- Vraylar® capsules (cariprazine) (included in the Antipsychotic Therapeutic Drug Class Review)
- Kovaltry® antihemophilic factor (recombinant)
- Idelvion® clotting Factor IX (recombinant)
- Xeljanz XR® tablets (tofacitinib)
- Epclusa® tablets (sofosbuvir/velpatasvir)
- **Therapeutic Drug Classes – Periodic Review**
  
  (Public comment prior to Board action)
  - Antidepressants, SSRIs
  - Antidepressants, Non-SSRIs
  - Antipsychotics
  - Stimulants
  - Analgesics, SA Narcotics
  - Analgesics, LA Narcotics

- **New Managed Therapeutic Drug Classes**
  
  (Public comment prior to Board action)

- **Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products**
  
  (Public comment prior to Board action)
  - Nucala® injection (mepolizumab)
  - 2016/17 Seasonal Influenza Vaccine

- **General Announcements**
  
  Selected FDA Safety Alerts

  FDA Drug Safety Communication: FDA warns about serious bleeding risk with over-the-counter antacid products containing aspirin
  

  Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR): Drug Safety Communication - Strengthened Kidney Warnings
  

  Loperamide (Imodium): Drug Safety Communication - Serious Heart Problems With High Doses From Abuse and Misuse
  

  Zecuity (sumatriptan) Migraine Patch: Drug Safety Communication - FDA Evaluating Risk of Burns and Scars
  

  FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects
  

  Multistate Outbreak of *Burkholderia cepacia* Infections
  
- Adjourn 8:30